Aquestive Therapeutics has successfully priced an underwritten public offering of its common stock to raise $85 million in gross proceeds. The company is selling 21,250,000 shares at a price of $4.00 per share. This significant capital raise is a strategic move to finance the commercialization of its key product candidate, Anaphylm™ (epinephrine) Sublingual Film, a novel treatment for severe, life-threatening allergic reactions. Assuming the product receives approval from the FDA, these funds will be critical for a successful launch.

The offering attracted strong interest from a group of institutional investors, demonstrating confidence in the company's prospects. The offering was led by RTW Investments, LP, and saw participation from other major firms, including Samsara BioCapital, EcoR1 Capital, and Perceptive Advisors. The transaction, which is being managed by a team of joint bookrunning managers including Leerink Partners, Cantor, and Oppenheimer & Co., is expected to close on or about August 15, 2025. This infusion of capital will not only support the Anaphylm™ launch but also provide the company with general working capital and resources for other corporate purposes, strengthening its financial position as it moves toward a new phase of commercial growth.